**Appendix Table D17. Risk of bias in randomized controlled clinical trials that examined efficacy of topiramate for migraine prevention in adults (sorted by year of publication)**

| **Reference** | **Masking of Treatment Status** | **Intention to Treat Analysis Preplanned** | **Allocation Concealment** | **Adequacy of Randomization** | **Selective Outcome Reporting** | **Risk of Bias** |
| --- | --- | --- | --- | --- | --- | --- |
| Storey, 200118 | Double-blind | No | Unclear | Yes (Topiramate group had no men and higher number of patients with concurrent preventative treatment, but the differences were not significant) | Unclear | Low |
| Edwards, 200319 | Double-blind | Yes | Unclear | Unclear | Unclear | Low |
| Silvestrini, 200320 | Double-blind | No | Unclear | Yes | Unclear | Low |
| Silberstein, 200321 | Double-blind | No | Unclear | Yes | Unclear | Medium |
| Brandes, 200422 | Double-blind | Yes | Clearly adequate | Yes | Unclear | Low |
| Silberstein, 200423 | Double-blind | Yes | Unclear | Yes | Unclear | Low |
| Mei, 200424 | Double-blind | No | Unclear | Unclear | Unclear | Medium |
| Bussone, 200525 | Double-blind | Yes | Unclear | Yes | Unclear | Low |
| Diamond, 200526 | Double-blind | Yes | Unclear | Previously reported22, 23, 43 | Unclear | Low |
| Silberstein, 200627 | Double-blind | Yes | Unclear | Not adequate. Topiramate 200mg/day group has lower % of women and higher % of men as compared to other groups, but the differences were not significant (previously reported) | Unclear | Medium |
| Mei, 200628 | Double-blind | Yes | Unclear | Yes | Unclear | Low |
| Silberstein, 200629 | Double-blind | Yes | Unclear | Not reported | Unclear | Medium |
| Brandes, 200630 | Double-blind | Yes | Clearly adequate | Not adequate; the % of male patients were much lower in the topiramate100mg and 200mg groups, but the difference were not significant | Unclear | Medium |
| Silberstein, 200731 | Double-blind | Yes | Unclear | Yes | Unclear | Low |
| Lofland, 200732 | Double-blind | Yes | Unclear | Yes | Unclear | Low |
| Limmroth, 200733 | Double-blind | Yes | Unclear | Yes | Unclear | Low |
| Diener, 200734 | Double-blind | Yes | Unclear | Not adequate (Mean Beck Depression Inventory scores were higher in placebo as compared to topiramate, but the differences were not significant) | Unclear | Medium |
| Lainez, 200735 | Double-blind | No | Unclear | Yes | Unclear | Low |
| Freitag, 200736 | Double-blind | Yes | Unclear | Yes | Unclear | Low |
| Dahlof, 200737 | Double-blind | Yes | Unclear | Yes | Unclear | Low |
| Diener, 200738 | Double-blind | Yes | Unclear | Yes | Unclear | Medium |
| Dodick, 200739 | Double-blind | Yes | Unclear | Yes | Unclear | Low |
| Adelman, 200840 | Double-blind | No | Unclear | Yes | Unclear | Low |
| Silberstein, 200941 | Double-blind | Yes | Clearly adequate | Yes | Unclear | Low |
| Lipton, 201142 | Double-blind | Yes | Unclear | Yes | The study mentions the significance of the outcome: ≥50% and 75% reduction in headache days and migraine headache days, however, the results are not given | Low |